Kronos Bio, Inc.

NASDAQ:KRON

0.9 (USD) • At close November 7, 2024
Bedrijfsnaam Kronos Bio, Inc.
Symbool KRON
Munteenheid USD
Prijs 0.9
Beurswaarde 54,265,140
Dividendpercentage 0%
52-weken bereik 0.69 - 1.6
Industrie Biotechnology
Sector Healthcare
CEO Dr. Norbert W. Bischofberger Ph.D.
Website https://kronosbio.com

An error occurred while fetching data.

Over Kronos Bio, Inc.

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase

Vergelijkbare Aandelen

Immunic, Inc. logo

Immunic, Inc.

IMUX

1.18 USD

DermTech, Inc. logo

DermTech, Inc.

DMTK

0.094 USD

Pliant Therapeutics, Inc. logo

Pliant Therapeutics, Inc.

PLRX

15.19 USD

Marinus Pharmaceuticals, Inc. logo

Marinus Pharmaceuticals, Inc.

MRNS

0.359 USD

MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics

MLTX

50.67 USD

Personalis, Inc. logo

Personalis, Inc.

PSNL

4.32 USD

Sanara MedTech Inc. logo

Sanara MedTech Inc.

SMTI

33.91 USD

Lyra Therapeutics, Inc. logo

Lyra Therapeutics, Inc.

LYRA

0.265 USD

Hyperfine, Inc. logo

Hyperfine, Inc.

HYPR

0.97 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)